DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway
Abstract CDK4/6 are important regulators of cell cycle and their inhibitors have been approved as anti-cancer drugs. Here, we report a STING-dependent anti-tumor immune mechanism responsible for tumor suppression by CDK4/6 blockade. Clinical datasets show that in human tissues, CDK4 and CDK6 are over-expressed and their expressions are negatively correlated with patients’ overall survival and T cell infiltration. Deletion of Cdk4 or Cdk6 in tumor cells significantly reduce tumor growth. Mechanistically, we find that Cdk4 or Cdk6 deficiency contributes to an increased level of endogenous DNA damage, which triggers the cGAS-STING signaling pathway to activate type I interferon response. Knockout of Sting is sufficient to reverse and partially reverse the anti-tumor effect of Cdk4 and Cdk6 deficiency respectively. Therefore, our findings suggest that CDK4/6 inhibitors may enhance anti-tumor immunity through the STING-dependent type I interferon response..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Communications Biology - 6(2023), 1, Seite 18 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huimin Fan [VerfasserIn] |
|---|
| Links: |
doi.org [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1038/s42003-023-05412-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
DOAJ091918995 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ091918995 | ||
| 003 | DE-627 | ||
| 005 | 20240412220013.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240412s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s42003-023-05412-x |2 doi | |
| 035 | |a (DE-627)DOAJ091918995 | ||
| 035 | |a (DE-599)DOAJfad57a470da443a6b7b00c062fc9e071 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 050 | 0 | |a QH301-705.5 | |
| 100 | 0 | |a Huimin Fan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a DNA damage induced by CDK4 and CDK6 blockade triggers anti-tumor immune responses through cGAS-STING pathway |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract CDK4/6 are important regulators of cell cycle and their inhibitors have been approved as anti-cancer drugs. Here, we report a STING-dependent anti-tumor immune mechanism responsible for tumor suppression by CDK4/6 blockade. Clinical datasets show that in human tissues, CDK4 and CDK6 are over-expressed and their expressions are negatively correlated with patients’ overall survival and T cell infiltration. Deletion of Cdk4 or Cdk6 in tumor cells significantly reduce tumor growth. Mechanistically, we find that Cdk4 or Cdk6 deficiency contributes to an increased level of endogenous DNA damage, which triggers the cGAS-STING signaling pathway to activate type I interferon response. Knockout of Sting is sufficient to reverse and partially reverse the anti-tumor effect of Cdk4 and Cdk6 deficiency respectively. Therefore, our findings suggest that CDK4/6 inhibitors may enhance anti-tumor immunity through the STING-dependent type I interferon response. | ||
| 653 | 0 | |a Biology (General) | |
| 700 | 0 | |a Wancheng Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Yanqiong Zeng |e verfasserin |4 aut | |
| 700 | 0 | |a Ying Zhou |e verfasserin |4 aut | |
| 700 | 0 | |a Meiling Gao |e verfasserin |4 aut | |
| 700 | 0 | |a Liping Yang |e verfasserin |4 aut | |
| 700 | 0 | |a Hao Liu |e verfasserin |4 aut | |
| 700 | 0 | |a Yueyue Shi |e verfasserin |4 aut | |
| 700 | 0 | |a Lili Li |e verfasserin |4 aut | |
| 700 | 0 | |a Jiayuan Ma |e verfasserin |4 aut | |
| 700 | 0 | |a Jiayin Ruan |e verfasserin |4 aut | |
| 700 | 0 | |a Ruyun Cao |e verfasserin |4 aut | |
| 700 | 0 | |a Xiaoxia Jin |e verfasserin |4 aut | |
| 700 | 0 | |a Jian Chen |e verfasserin |4 aut | |
| 700 | 0 | |a Genhong Cheng |e verfasserin |4 aut | |
| 700 | 0 | |a Heng Yang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Communications Biology |d Nature Portfolio, 2018 |g 6(2023), 1, Seite 18 |w (DE-627)DOAJ00013418X |x 23993642 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2023 |g number:1 |g pages:18 |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s42003-023-05412-x |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/fad57a470da443a6b7b00c062fc9e071 |z kostenfrei |
| 856 | 4 | 0 | |u https://doi.org/10.1038/s42003-023-05412-x |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2399-3642 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2023 |e 1 |h 18 | ||